Many people living with allergic bronchopulmonary aspergillosis (ABPA) also use inhaled steroid inhalers such as Symbicort, Fostair, Seretide or Clenil. It’s common to feel confused about whether these inhalers help, whether they should be continued, or whether they could cause harm.
This guide explains what inhaled steroids do, what they don’t do, and how they fit into the treatment of ABPA, asthma, and bronchiectasis.
1. Understanding the basics
What are inhaled steroids?
Inhaled corticosteroids (ICS) are medications breathed directly into the lungs to reduce airway inflammation, especially in asthma. Combination inhalers (e.g., Symbicort, Fostair) contain a steroid + a long-acting bronchodilator.
What they don’t do
Inhaled steroids do not treat ABPA itself.
ABPA is caused by an immune over-reaction to Aspergillus in the lungs. This reaction sits too deep in the airways for inhaled steroids to reach, and the inflammation is too strong for inhaled doses to control.
This is why ABPA flares are treated with:
-
Oral steroids, or
-
Biologics, such as mepolizumab, benralizumab, dupilumab or omalizumab.
2. Why inhaled steroids are still useful for many ABPA patients
Although inhaled steroids don’t treat ABPA directly, most people with ABPA also have asthma.
In asthma:
-
the airways are twitchy
-
inflamed
-
narrow easily
-
and respond well to inhaled steroids
If your symptoms include wheeze, chest tightness, breathlessness that varies from day to day, or a good response to your reliever inhaler, there is a strong chance that asthma is part of your condition.
In those cases, inhaled steroids can be very helpful in keeping the asthma component under control.
3. When inhaled steroids may offer little benefit
Some patients with ABPA have:
-
minimal asthma
-
mainly bronchiectasis
-
or are fully controlled on a biologic
In these situations, inhaled steroids might not provide much additional benefit and occasionally can increase the risk of airway infections, especially in people with significant bronchiectasis.
This is why doctors sometimes sound vague: the answer genuinely depends on your individual mix of ABPA, asthma, and bronchiectasis.
4. How biologics change the picture
Biologics used for ABPA and asthma (e.g., benralizumab, mepolizumab, dupilumab) reduce airway inflammation far more effectively than inhaled steroids. Once a patient is stable on a biologic, many specialists will slowly reduce the inhaled steroid dose if asthma symptoms remain well-controlled.
This does not happen quickly — it is done gradually and only if your breathing tests and symptoms stay stable.
5. Why there is no simple “yes” or “no” answer
Doctors often hesitate to give a straight answer because inhaled steroids can be:
-
Essential for asthma
-
Optional for mild asthma
-
Less useful if ABPA is the main issue
-
Potentially overused in some bronchiectasis patients
-
Safely reduced in people doing well on biologics
Your treatment has to sit in the right place on that spectrum.
6. Questions that can help you get a clear answer from your own team
Many patients say they receive vague responses. These direct questions can help:
✔ “Am I using this inhaler for my asthma, or for my ABPA?”
(If it’s for ABPA, that usually signals a misunderstanding.)
✔ “Do you think my asthma is active, and is the dose of inhaled steroid still appropriate?”
This invites your clinician to be specific.
✔ “If I stay stable on my biologic, could we review the inhaled steroid dose in the future?”
This aligns with typical specialist practice.
7. The bottom line
-
Inhaled steroids do not treat ABPA itself.
-
They are helpful if you also have asthma — which many ABPA patients do.
-
They may be less useful if asthma is mild or absent, especially in pure bronchiectasis.
-
When patients stabilise on biologics, inhaled steroid doses are often reviewed and sometimes reduced.
-
The best approach is individual: the right treatment mix varies from patient to patient.
If you’re unsure what role your inhaler is playing, it’s absolutely reasonable to ask your specialist to explain exactly why you’re on it and whether the dose is still right for you.
Latest News posts
News archive